Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Receivables - Other (2023 - 2025)

Historic Receivables - Other for Tonix Pharmaceuticals Holding (TNXP) over the last 3 years, with Q3 2025 value amounting to $1.7 million.

  • Tonix Pharmaceuticals Holding's Receivables - Other fell 2187.35% to $1.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.7 million, marking a year-over-year decrease of 2187.35%. This contributed to the annual value of $953000.0 for FY2024, which is 37650.0% up from last year.
  • Tonix Pharmaceuticals Holding's Receivables - Other amounted to $1.7 million in Q3 2025, which was down 2187.35% from $2.0 million recorded in Q2 2025.
  • In the past 5 years, Tonix Pharmaceuticals Holding's Receivables - Other registered a high of $4.6 million during Q4 2023, and its lowest value of $242000.0 during Q1 2024.
  • For the 3-year period, Tonix Pharmaceuticals Holding's Receivables - Other averaged around $1.7 million, with its median value being $1.6 million (2023).
  • Its Receivables - Other has fluctuated over the past 5 years, first crashed by 7923.75% in 2024, then skyrocketed by 43264.46% in 2025.
  • Over the past 3 years, Tonix Pharmaceuticals Holding's Receivables - Other (Quarter) stood at $4.6 million in 2023, then crashed by 79.24% to $953000.0 in 2024, then surged by 75.03% to $1.7 million in 2025.
  • Its last three reported values are $1.7 million in Q3 2025, $2.0 million for Q2 2025, and $1.3 million during Q1 2025.